Buyback of up to 81 crore at 27 per share via tender route

Buyback at over 10% premiumCorporate Actions View source PDF Explain this filing

NECLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹20.95

prior close

₹20.94

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.1%+1.2% vs market

On the reaction day the stock moved 1.2 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.0

15m

-0.0

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

+0.1-1.1+1.2

Next day

-2.2-3.5+1.2

+0.0-1.6+1.6

+0.4-2.2+2.6

+0.2-1.8+2.0

+0.5-1.5+2.0

+1.1-1.6+2.8

15d

-8.9-2.0-6.9

-8.7+0.7-9.4

-34.6-3.8-30.8

-43.5-9.8-33.7

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Nectar Lifesciences approved buyback of up to 3 crore equity shares at INR 27 each, totaling up to INR 81 crore through tender offer. This represents 13.38% of paid-up capital. Buyback price is about 90% above the closing price of INR 14.16 on the intimation date. Promoters will not participate. Funded from free reserves. Record date is December 24, 2025.

Likely market impact

Significant buyback at large premium rewards shareholders. Promoters not participating means full entitlement goes to public investors.